No Waiting Period Required Between Vancomycin and Dalbavancin
You can start dalbavancin (Dalvance) immediately after completing IV vancomycin without any mandatory waiting period. There is no pharmacological interaction or safety concern that requires a washout period between these two glycopeptide antibiotics.
Key Clinical Considerations
Why No Waiting Period is Needed
- Both are glycopeptide antibiotics with similar mechanisms of action (cell wall synthesis inhibition), but dalbavancin does not require vancomycin clearance before initiation 1
- No drug-drug interactions are documented between vancomycin and dalbavancin in the FDA labeling
- Clinical practice supports immediate transition: The FDA label and clinical trials do not specify any washout period when switching from other glycopeptides 1
Important Safety Monitoring
While no waiting period is required, you should be aware of:
Cross-sensitivity risk: Since both are glycopeptides, patients with vancomycin hypersensitivity may have cross-reactivity with dalbavancin. The FDA label specifically warns: "Before using DALVANCE, inquire carefully about previous hypersensitivity reactions to other glycopeptides. Due to the possibility of cross-sensitivity, carefully monitor for signs of hypersensitivity during treatment with DALVANCE in patients with a history of glycopeptide allergy" 1
Infusion-related reactions: Administer dalbavancin over 30 minutes to minimize risk of flushing, urticaria, pruritus, rash, or back pain 1
Practical Implementation
Dosing Regimen
- Standard adult dose: 1,500 mg as a single dose OR 1,000 mg followed by 500 mg one week later 1
- Renal adjustment: If CrCl <30 mL/min (not on dialysis), reduce to 1,125 mg single dose or 750 mg/375 mg two-dose regimen 1
- Infusion time: Always administer over 30 minutes via IV infusion 1
Clinical Advantages of Transition
Dalbavancin offers significant benefits over continuing vancomycin:
- Reduced nephrotoxicity: 3.7% vs 9.3% with vancomycin (P=0.039) 2
- Once-weekly dosing eliminates need for daily IV access and monitoring 3
- Lower infection-related readmission rates (17% vs 28% with standard of care) 4
- Cost savings of approximately $5,133 per patient when avoiding hospitalization 5
Common Pitfall to Avoid
Do not use saline-based infusion solutions with dalbavancin as they may cause precipitation. Only use 5% Dextrose Injection for dilution and line flushing 1